Repligen Stock News

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present vi

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt

NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RGEN, ZEN, UAL, DLTR, and BNTX. … Full story available on Benzinga.com

SAN FRANCISCO , March 10, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Biopharmaceutical Bioseparation Systems - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 17; Released: February 2022 Executive Pool: 4113 Companies: 52 - Players covered include 3M Purification Inc.; Agilent Technologies, Inc.; Alfa Wassermann Separation Technologies LLC; Flottweg Separation Technology; GE Healthcare Life Sciences; GEA Westfalia Separator Group GmbH; KNAUER Wissenschaftliche Geräte GmbH; Konik Nanobiotech SL; Merck KGaA; Pall Corporation; ProMetic Life Sciences Inc.; Repligen Corp.; Sartorius Stedim Biotech; Thermo Fischer Scientific Inc.; Tosoh Bioscience Inc.; YMC Europe GMBH and Others.

LRT Capital Management, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here.

Brokerages forecast that Repligen Co. will report $183.55 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Repligen''s…

Smart Beta ETF report for RFG

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Needham lowered Fiverr International Ltd. (NYSE: FVRR) price target from $205 to $100. Fiverr International shares gained 2% to $80.00 in pre-market trading. Wedbush cut the price target on Shake S

Repligen Corp (NASDAQ: RGEN ) reported Q4 FY21 sales of $186.5 million , up 72% Y/Y as reported and 73% at constant currency, with organic growth of 69%, beating the consensus of $179.29 million. The base business accounted for 64% of revenue, COVID-related sales accounted for 33% of revenue, and … Full story available on Benzinga.com

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Repligen press release (RGEN): Q4 Non-GAAP EPS of $0.81 beats by $0.16.Revenue of $186.52M (+71.7% Y/Y) beats by $8.25M.For FY2022, the company expects total revenue is expected to…